M&A / Deals Merck KGaA and Remepy join forces to develop combo drug-digital therapies Pharmaceutical TechnologyMerck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.Read full story pharminent April 28, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication. Read full story Post navigation Previous: Novartis shares fall as Entresto sales weakenNext: GSK eyes October FDA verdict on chronic hep B drug Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026